In the past six months, new surgical and medical options became available to treat patients with Clostridium difficile. As the options for treating the infection have increased, so too have the questions about who should get what treatments and when…Fidaxomicin’s approval could “potentially be an important change” in C. difficile treatment, given the decreased risk for recurrent infection in patients with non-NAP1 strains but that must be balanced against the cost, said Darrell Pardi, MD, associate professor of medicine at Mayo Clinic, in Rochester, Minn.

Anesthesiology News, by Christina Frangou 12/2011

Tags: GI, Mayo Clinic Rochester